Drug and xenobiotic biotransforrnation in the blood-brain barrier: a neglected issue

被引:41
作者
Agundez, Jose A. G. [1 ,2 ]
Jimenez-Jimenez, Felix J. [3 ]
Alonso-Navarro, Hortensia [3 ]
Garcia-Martin, Elena [2 ,4 ]
机构
[1] Univ Extremadura, Dept Pharmacol, Caceres 10071, Spain
[2] ISCIII Res Network Adverse React Allergens & Drug, Madrid, Spain
[3] Hosp Univ Sureste, Neurol Sect, Madrid, Spain
[4] Univ Extremadura, Dept Biochem Mol Biol & Genet, Caceres 10071, Spain
来源
FRONTIERS IN CELLULAR NEUROSCIENCE | 2014年 / 8卷
关键词
blood-brain barrier; drug metabolizing enzymes; expression profiling; CNS drug; drug response; METABOLIZING-ENZYMES; IN-VITRO; ABC TRANSPORTERS; CYTOCHROMES P450; CYP2J2; PHARMACOGENOMICS; EXPRESSION; POLYMORPHISMS; INVOLVEMENT; INHIBITION;
D O I
10.3389/fncel.2014.00335
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Drug biotransformation is a crucial mechanism for facilitating the elimination of chemicals from the organism and for decreasing their pharmacological activity. Published evidence suggests that brain drug metabolism may play a role in the development of adverse drug reactions and in the clinical response to drugs and xenobiotics. The blood-brain barrier (BBB) has been regarded mainly as a physical barrier for drugs and xenobiotics, and little attention has been paid to the BBB as a drug-metabolizing barrier. The presence of drug-metabolizing enzymes in the BBB is likely to have functional implications because local metabolism may inactivate drugs or may modify the drug's ability to cross the BBB, thus modifying drug response and the risk of developing adverse drug reactions. In this perspective paper, we discuss the expression of relevant xenobiotic metabolizing enzymes in the brain and in the BBB, and we cover current advances and future directions on the potential role of these BBB drug-metabolizing enzymes as modifiers of drug response.
引用
收藏
页数:4
相关论文
共 48 条
[1]  
Agundez J. A., 2014, CYP2D6 GENETICS PHAR, P118
[2]   Anti-Parkinson's disease drugs and pharmacogenetic considerations [J].
Agundez, Jose A. G. ;
Garcia-Martin, Elena ;
Alonso-Navarro, Hortensia ;
Javier Jimenez-Jimenez, Felix .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (07) :859-874
[3]  
Agúndez JAG, 2009, EXPERT OPIN DRUG MET, V5, P607, DOI [10.1517/17425250902970998 , 10.1517/17425250902970998]
[4]   Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases [J].
Aiba, Isamu ;
Yamasaki, Tomoaki ;
Shinki, Toshimasa ;
Izumi, Shunsuke ;
Yamamoto, Keiko ;
Yamada, Sachiko ;
Terato, Hiroaki ;
Ide, Hiroshi ;
Ohyama, Yoshihiko .
STEROIDS, 2006, 71 (10) :849-856
[5]   Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. [J].
Bournique, B ;
Lemarié, A .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1149-1152
[6]   Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P4501B1 [J].
Choudhary, D ;
Jansson, I ;
Stoilov, I ;
Sarfarazi, M ;
Schenkman, JB .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) :840-847
[7]   ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier [J].
Dauchy, Sandrine ;
Dutheil, Fabien ;
Weaver, Richard J. ;
Chassoux, Francine ;
Daumas-Duport, Catherine ;
Couraud, Pierre-Olivier ;
Scherrmann, Jean-Michel ;
De Waziers, Isabelle ;
Decleves, Xavier .
JOURNAL OF NEUROCHEMISTRY, 2008, 107 (06) :1518-1528
[9]   Pre-systemic metabolism of orally administered drugs and strategies to overcome it [J].
de Sousa, Irene Pereira ;
Bernkop-Schnuerch, Andreas .
JOURNAL OF CONTROLLED RELEASE, 2014, 192 :301-309
[10]   Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier [J].
Decleves, Xavier ;
Jacob, Aude ;
Yousif, Salah ;
Shawahna, Ramzi ;
Potin, Sophie ;
Scherrmann, Jean-Michel .
CURRENT DRUG METABOLISM, 2011, 12 (08) :732-741